Development of a TMErisk model based on immune infiltration in tumour microenvironment to predict prognosis of immune checkpoint inhibitor treatment in hepatocellular carcinoma

Yan, Zi-Jun; Yu, Chu-Ting; Chen, Lei; Wang, Hongyang

doi:10.1093/bib/bbad067

Cited by 4 publications

(2 citation statements)

References 55 publications

(87 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The differential expression of immune checkpoint molecules in the high- and low-risk groups was explored using the Wilcoxon test. The same method was used to analyze the difference in HLA expression ( 29 ).…”

Section: Methodsmentioning

confidence: 99%

A disulfidptosis-related glucose metabolism and immune response prognostic model revealing the immune microenvironment in lung adenocarcinoma

Zhang,

Li,

Wang

et al. 2024

Front. Immunol.

View full text Add to dashboard Cite

BackgroundLung adenocarcinoma accounts for the majority of lung cancer cases and impact survival rate of patients severely. Immunotherapy is an effective treatment for lung adenocarcinoma but is restricted by many factors including immune checkpoint expression and the inhibitory immune microenvironment. This study aimed to explore the immune microenvironment in lung adenocarcinoma via disulfidptosis.MethodsPublic datasets of lung adenocarcinoma from the TCGA and GEO was adopted as the training and validation cohort. Based on the differences in the expression of disulfidptosis -related genes, a glucose metabolism and immune response prognostic model was constructed. The prognostic value and clinical relationship of the model were further explored. Immune-related analyses were performed according to CIBERSORT, ssGSEA, TIDE, IPS.ResultsWe verified that the model could accurately predict the survival expectancy of lung adenocarcinoma patients. Patients with lung adenocarcinoma and a low-risk score had better survival outcomes according to the model. Moreover, the high-risk group tended to have an immunosuppressive effect, as reflected by the immune cell components, phenotypes and functions. We also found that the clinically relevant immune checkpoint CTLA-4 was significantly higher in low-risk group (P<0.05), indicating that the high-risk group may suffer worse tumor immunotherapy efficacy. Finally, we found that this model has accurate predictive value for the efficacy of immune checkpoint blockade in non-small cell lung cancer (P<0.05).ConclusionThe prognostic model demonstrated the feasibility of predicting survival and immunotherapy efficacy via disulfidptosis-related genes and will facilitate the development of personalized anticancer therapy.

show abstract

Section: Methodsmentioning

confidence: 99%

A disulfidptosis-related glucose metabolism and immune response prognostic model revealing the immune microenvironment in lung adenocarcinoma

Zhang,

Li,

Wang

et al. 2024

Front. Immunol.

View full text Add to dashboard Cite

show abstract

“…Examining melanoma trial results, the study concludes that high CD8+ T-cell content is an effective indicator of ICB response only when associated with a low TGFβ signature [52]. The TME risk signatures developed for lung [53] and HCC [54], as well as the immune checkpoint inhibitor scoring system (IMS) for bladder cancer [55], provide additional informative examples, defining TME features associated with anti-tumour immunity and ICB response. In each of these signatures or scoring systems, matrisome components are abundant, with commonalities regarding TGFβ signatures, collagen regulation, and immune content.…”

Section: Matrix Signatures Associated With Immune Evasion and Immune ...mentioning

confidence: 98%

Targets in the Tumour Matrisome to Promote Cancer Therapy Response

Jalil,

Henry,

Cameron

2024

Cancers

View full text Add to dashboard Cite

The extracellular matrix (ECM) is composed of complex fibrillar proteins, proteoglycans, and macromolecules, generated by stromal, immune, and cancer cells. The components and organisation of the matrix evolves as tumours progress to invasive disease and metastasis. In many solid tumours, dense fibrotic ECM has been hypothesised to impede therapy response by limiting drug and immune cell access. Interventions to target individual components of the ECM, collectively termed the matrisome, have, however, revealed complex tumour-suppressor, tumour-promoter, and immune-modulatory functions, which have complicated clinical translation. The degree to which distinct components of the matrisome can dictate tumour phenotypes and response to therapy is the subject of intense study. A primary aim is to identify therapeutic opportunities within the matrisome, which might support a better response to existing therapies. Many matrix signatures have been developed which can predict prognosis, immune cell content, and immunotherapy responses. In this review, we will examine key components of the matrisome which have been associated with advanced tumours and therapy resistance. We have primarily focussed here on targeting matrisome components, rather than specific cell types, although several examples are described where cells of origin can dramatically affect tumour roles for matrix components. As we unravel the complex biochemical, biophysical, and intracellular transduction mechanisms associated with the ECM, numerous therapeutic opportunities will be identified to modify tumour progression and therapy response.

show abstract

A scoring model for the expression of genes related to programmed cell death predicts immunotherapy response and prognosis in lung adenocarcinoma

Jia,

Liang,

et al. 2024

Discov Onc

View full text Add to dashboard Cite

Development of a TMErisk model based on immune infiltration in tumour microenvironment to predict prognosis of immune checkpoint inhibitor treatment in hepatocellular carcinoma

Cited by 4 publications

References 55 publications

A disulfidptosis-related glucose metabolism and immune response prognostic model revealing the immune microenvironment in lung adenocarcinoma

A disulfidptosis-related glucose metabolism and immune response prognostic model revealing the immune microenvironment in lung adenocarcinoma

Targets in the Tumour Matrisome to Promote Cancer Therapy Response

A scoring model for the expression of genes related to programmed cell death predicts immunotherapy response and prognosis in lung adenocarcinoma

Contact Info

Product

Resources

About